All In Biotech

Drug Trial Radar · NCT01147250

Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate Cardiovascular Outcomes During Treatment With Lixisenatide in Type 2 Diabetic Patients After an Acute Coronary Syndrome

Last checked: Nov 20, 2026Latest source record: Dec 20, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 6,068 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

6,068

Actual

Start

Jun 2010

Primary completion

Feb 2015

Study completion Feb 2015

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Jun 22, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: \- To demonstrate that lixisenatide can reduce cardiovascular (CV) morbidity and mortality (composite endpoint of CV death, non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable angina) compared to placebo in type 2 diabetic participants who recently experienced an acute coronary syndrome (ACS) event. Secondary Objectives: To demonstrate that when compared to placebo, lixisenatide can reduce: * composite endpoint of CV death, non-fatal MI, non-fatal stroke, hospitalization for unstable angina, or hospitalization for heart failure. * composite endpoint of CV death, non-fatal MI, non-fatal stroke, hospitalization for unstable angina, hospitalization for heart failure, or coronary revascularization procedure. * urinary albumin excretion (based on the urinary albumin/creatinine ratio). To assess the safety and tolerability of lixisenatide.

Conditions

  • Acute Coronary Syndrome

Interventions

  • Lixisenatide (AVE0010)Drug

    Pharmaceutical form: Sterile aqueous solution; Route of administration: Subcutaneous within 1-hour before breakfast using self-injector pen device (Opticlik®). If the maintenance dose of 20 mcg was not tolerated, dose could be reduced to 15 or 10 mcg.

  • PlaceboDrug

    Pharmaceutical form: Sterile aqueous solution; Route of administration: Subcutaneous within 1-hour before breakfast.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to First Occurence of Primary CV Event: CV Death, Non-Fatal MI, Non-Fatal Stroke or Hospitalization for Unstable AnginaTime frame: From randomization up to the end of study (median follow-up of 25 months)

Locations

829 sites in 49 countries. Site status is shown where the registry gives one.

  • Investigational Site Number 840415

    Birmingham, Alabama

  • Investigational Site Number 840307

    Foley, Alabama

  • Investigational Site Number 840692

    Mobile, Alabama

  • Investigational Site Number 840037

    Mobile, Alabama

  • Investigational Site Number 840210

    Mobile, Alabama

  • Investigational Site Number 840326

    Muscle Shoals, Alabama

  • Investigational Site Number 840393

    Toney, Alabama

  • Investigational Site Number 840656

    Mesa, Arizona

  • Investigational Site Number 840506

    Phoenix, Arizona

  • Investigational Site Number 840520

    Phoenix, Arizona

  • Investigational Site Number 840322

    Phoenix, Arizona

  • Investigational Site Number 840250

    Tempe, Arizona

  • Investigational Site Number 840042

    Tucson, Arizona

  • Investigational Site Number 840303

    Hot Springs, Arkansas

  • Investigational Site Number 840184

    Jonesboro, Arkansas

  • Investigational Site Number 840361

    Little Rock, Arkansas

  • Investigational Site Number 840023

    Little Rock, Arkansas

  • Investigational Site Number 840706

    Anaheim, California

  • Investigational Site Number 840497

    Anaheim, California

  • Investigational Site Number 840667

    Downey, California

  • Investigational Site Number 840150

    Fresno, California

  • Investigational Site Number 840624

    Hawthorne, California

  • Investigational Site Number 840623

    Inglewood, California

  • Investigational Site Number 840636

    Inglewood, California

  • Investigational Site Number 840455

    La Mesa, California

  • Investigational Site Number 840240

    Loma Linda, California

  • Investigational Site Number 840262

    Long Beach, California

  • Investigational Site Number 840606

    Long Beach, California

  • Investigational Site Number 840694

    Los Angeles, California

  • Investigational Site Number 840431

    Los Angeles, California

  • Investigational Site Number 840135

    Los Angeles, California

  • Investigational Site Number 840314

    Merced, California

  • Investigational Site Number 840290

    Mission Viejo, California

  • Investigational Site Number 840592

    National City, California

  • Investigational Site Number 840275

    Northridge, California

  • Investigational Site Number 840654

    Oakland, California

  • Investigational Site Number 840351

    Orange, California

  • Investigational Site Number 840689

    Orange, California

  • Investigational Site Number 840582

    Pomona, California

  • Investigational Site Number 840346

    Port Hueneme, California

Showing 40 of 829 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.